Hanfei Qi

Hanfei Qi

Auto-generated profile, based on publicly available information

Hanfei Qi

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
DSDaniel H. Shu
Daniel H. Shu
WHWon Jin Ho
Won Jin Ho
LKLuciane Kagohara
Luciane Kagohara
AGAlexander Girgis
Alexander Girgis
SSSarah M. Shin
Sarah M. Shin
MYMark Yarchoan
Mark Yarchoan

20 March 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KSKara M. Schenk
Kara M. Schenk
JDJulie Stein Deutsch
Julie Stein Deutsch
SCSUNANDANA CHANDRA
SUNANDANA CHANDRA
DDDiwakar Davar
Diwakar Davar
ZEZeynep Eroglu
Zeynep Eroglu
ELEvan J Lipson
Evan J Lipson
PURPOSE: Cancer-related mortality rates among kidney transplant recipients (KTR) are high, but these patients have largely been excluded from trials of immune checkpoint inhibitors because of immunosuppression and risk of treatment-related allograft loss (TRAL). We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers. METHODS: Adult KTR with advanced melanoma or basal, cutaneous squamous, or Merkel cell carcinomas were eligible. Immunosuppression was standardized to TACRO (serum trough 2-5 ng/mL) + PRED 5 mg once daily. Patients then received NIVO 480 mg IV once every 4 weeks. The primary composite end point was partial or complete (tumor) response (CR) or stable disease per RECIST v1.1 without allograft loss at 16W. Patients with progressive disease (PD) could receive IPI 1 mg/kg IV + NIVO 3 mg/kg once every 3 weeks × 4 followed by NIVO. Donor-derived cell-free DNA (dd-cfDNA) levels were measured approximately once every 2 weeks as a potential predictor of allograft rejection. RESULTS: Among eight evaluable patients, none met the trial's primary end point. All eight patients experienced PD on NIVO + TACRO + PRED; TRAL occurred in one patient. Six patients then received IPI + NIVO + TACRO + PRED. Best overall responses: two CR (one with TRAL) and four PD (one with TRAL). In total, 7 of 8 pre-NIVO tumor biopsies contained a paucity of infiltrating immune cells. In total, 2 of 5 on-NIVO biopsies demonstrated moderate immune infiltrates; both patients later experienced a CR to IPI + NIVO. In 2 of 3 patients with TRAL, dd-cfDNA elevations occurred 10 and 15 days before increases in serum creatinine. CONCLUSION: In most KTR with advanced skin cancer, TACRO + PRED provides insufficient allograft protection and compromises immune-mediated tumor regression after administration of NIVO ± IPI. Elevated dd-cfDNA levels can signal treatment-related allograft rejection earlier than rises in serum creatinine.

2 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMark C. Markowski
Mark C. Markowski
MTMary-Ellen Taplin
Mary-Ellen Taplin
RARahul Aggarwal
Rahul Aggarwal
LSLaura A. Sena
Laura A. Sena
HWHao Wang
Hao Wang
EAEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we report the results of a multicenter, single arm Phase 2 study (NCT03554317) enrolling 45 patients with heavily pretreated mCRPC who received BAT (testosterone cypionate, 400 mg intramuscularly every 28 days) with the addition of nivolumab (480 mg intravenously every 28 days) following three cycles of BAT monotherapy. The primary endpoint of a confirmed PSA50 response rate was met and estimated at 40% (N = 18/45, 95% CI: 25.7–55.7%, P = 0.02 one-sided against the 25% null hypothesis). Sixteen of the PSA50 responses were achieved before the addition of nivolumab. Secondary endpoints included objective response rate (ORR), median PSA progression-free survival, radiographic progression-free survival (rPFS), overall survival (OS), and safety/tolerability. The ORR was 24% (N = 10/42). Three of the objective responses occurred following the addition of nivolumab. After a median follow-up of 17.9 months, the median rPFS was 5.6 (95% CI: 5.4–6.8) months, and median OS was 24.4 (95% CI: 17.6–31.1) months. BAT/nivolumab was well tolerated, resulting in only five (11%) drug related, grade-3 adverse events. In a predefined exploratory analysis, clinical response rates correlated with increased baseline levels of intratumoral PD-1 + T cells. In paired metastatic tumor biopsies, BAT induced pro-inflammatory gene expression changes that were restricted to patients achieving a clinical response. These data suggest that BAT may augment antitumor immune responses that are further potentiated by immune checkpoint blockade.

9 February 2024 in Science Advances
Verified
Journal Article
Open access
JWJunke Wang
Junke Wang
JGJessica Gai
Jessica Gai
TZTengyi Zhang
Tengyi Zhang
NNNan Niu
Nan Niu
HQHanfei Qi
Hanfei Qi
Lei ZhengLei Zheng
Lei Zheng
Radiotherapy is hypothesized to have an immune-modulating effect on the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) to sensitize it to anti–PD-1 antibody (a–PD-1) treatment. We collected paired pre- and posttreatment specimens from a clinical trial evaluating combination treatment with GVAX vaccine, a–PD-1, and stereotactic body radiation (SBRT) following chemotherapy for locally advanced PDACs (LAPC). With resected PDACs following different neoadjuvant therapies as comparisons, effector cells in PDACs were found to skew toward a more exhausted status in LAPCs following chemotherapy. The combination of GVAX/a–PD-1/SBRT drives TME to favor antitumor immune response including increased densities of GZMB + CD8 + T cells, T H 1, and T H 17, which are associated with longer survival, however increases immunosuppressive M2-like tumor-associated macrophages (TAMs). Adding SBRT to GVAX/a–PD-1 shortens the distances from PD-1 + CD8 + T cells to tumor cells and to PD-L1 + myeloid cells, which portends prolonged survival. These findings have guided the design of next radioimmunotherapy studies by targeting M2-like TAM in PDACs.

24 November 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MBMarina Baretti
Marina Baretti
AKAllison M. Kirk
Allison M. Kirk
BLBrian H. Ladle
Brian H. Ladle
ZKZeal Kamdar
Zeal Kamdar
KBKayla J. Bendinelli
Kayla J. Bendinelli
MYMark Yarchoan
Mark Yarchoan
Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer affecting children and young adults that is driven by a chimeric protein, DNAJ-PKAc. The development of molecular inhibitors of DNAJ-PKAc has been hampered by unacceptable on-target toxicity, but the chimera results in a tumor-specific antigen (neoantigen) that may be targeted immunologically. Here we conducted a phase 1 clinical trial of a therapeutic peptide vaccine targeting DNAJ-PKAc (FLC-Vac), in combination with nivolumab and ipilimumab, in children and adults with advanced FLC, who had not previously received immune checkpoint therapy. The primary objectives were safety and T cell responses after week 10 (priming phase). Of the 16 patients enrolled, 12 completed the vaccine priming phase and were evaluable for both immunological and clinical endpoints. The median age was 24 years (range 12–47 years). Grade 3 treatment-related adverse events were reported by six patients (37.5%). DNAJ-PKAc-specific T cell responses were detected in 9 of 12 patients after treatment. In the subset of patients who completed the initial priming phase the disease control rate was 75% (9/12), with three partial responses (25%). All patients with clinical responses also had DNAJ-PKAc-specific T cell responses, from which we identified multiple class-II-restricted T cell receptors with specificity for DNAJ-PKAc. Correlates of response included both functional neoantigen reactivity and changes in T cell receptor repertoire features over time. Immune escape in two patients corresponded with immune exhaustion rather than neoantigen escape or human leukocyte antigen loss. Our findings demonstrate the potential for therapeutic vaccines targeting ‘undruggable’ oncogenic drivers and suggest a rubric for evaluating effective anti-neoantigen immunity. ClinicalTrials.gov identifier: NCT04248569.

23 May 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
PAParul Agarwal
Parul Agarwal
MGMatthew Guo
Matthew Guo
KMKabeer Munjal
Kabeer Munjal
HQHanfei Qi
Hanfei Qi
RPRose Parkinson
Rose Parkinson
AOArsen Osipov
Arsen Osipov
Purpose: Borderline resectable pancreatic ductal adenocarcinoma (PDAC) is treated with perioperative chemotherapy and surgical resection with or without stereotactic body radiotherapy (SBRT), but long-term survival is rare. GVAX is a GM-CSF–secreting vaccine that activates T-cell immunity against tumor-associated antigens. This multicenter phase II clinical trial evaluated the safety and immune effects of GVAX/cyclophosphamide/nivolumab and SBRT on the PDAC tumor microenvironment (TME). Patients and Methods: Patients received neoadjuvant mFOLFIRINOX or gemcitabine/nab-paclitaxel if intolerant to mFOLFIRINOX followed by combination immunotherapy and SBRT before surgical resection. The primary endpoint was CD8+ T-cell density in surgical specimens compared with in historic control samples treated with neoadjuvant mFOLFIRINOX and SBRT only. Pathologic response rate, overall survival, and exploratory immune evaluation of the TME are also reported. Results: Thirty-one patients were enrolled from January 2018 to July 2021. Eighteen patients received at least one dose of combined immunotherapy. Fourteen patients underwent definitive surgical resection, and one pathologic complete response was observed. At a median follow-up of 19.5 months, the median overall survival was 20.4 months (95% confidence interval, 18.2–not achieved). There was no difference in the mean CD8 T-cell density between study patients and historic control patients. Nonsignificant increases in the abundance score for specific immune cell subsets were observed in responders as compared with nonresponders. Conclusions: The addition of combined immunotherapy and SBRT was safe and feasible in this patient population. No difference was observed in the mean CD8 T-cell density between study patients and historic controls. These findings support the need for better characterization of how neoadjuvant immunotherapy may shift the phenotype of the PDAC TME.